Sage Journals: Discover world-class research

Abstract

Tourette syndrome is characterized by motor and vocal tics, frequently accompanied by attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, coprolalia, aggressive or self-injurious behavior, and learning disabilities. We investigated the height distribution and clinical characteristics of 38 consecutive patients with Tourette syndrome. Seventeen patients with Tourette syndrome (44.7%) were in the lower height quartile versus 25% from a control group of 44 patients with ADHD (P < .05). The mean standard deviation score differential (patient height - [target height]) was -1.12 ± 0.82 for patients in the first quartile (group A) compared with 0.42 ± 0.63 in taller patients with Tourette syndrome (group B) (P <. .001). The mean birthweight of boys in group A versus group B was 3023 ± 351 g and 3363 ± 486 g, respectively (P < .02); birthweight correlated with standard deviation score (r=.43) . Current weight relative to height was normal. Conduct disorder and/or self-injurious behavior were more common in group A patients (P < .05). Relative short stature appears common in Tourette syndrome, and its presence with other features may implicate a neurotransmitter system that interacts with neuroendocrine pathways, controlling height. (J Child Neurol 2002;17:200-204).

Get full access to this article

View all access options for this article.

References

American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, APA, 1994.

Coffey BJ , Park SP : Behavioral and emotional aspects of Tourette syndrome, review. Neurol Clin North Am 1997;15:277-289.

Price RA , Kidd KK , Cohen DJ , et al: A twin study of Tourette syndrome. Arch Gen Psychiatry 1985;42:815-820.

Walkup JT , LaBuda MC , Singer HS , et al: Family study and segregation analysis of Tourette's syndrome: Evidence for a mixed model of inheritance. Am J Hum Genet 1996;59:684-693.

Hamil Pvv , Drizd TA , Johnson CA : Physical growth: National Center for Health Statistics percentiles . Am J Clin Nutr 1979;32:609-610.

Greulich WW , Pyle SI : Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford, CT, Stanford University Press, 1959.

Bayley N. , Pinneau S. : Tables for predicting adult height from skeletal age: Revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;50:423-441.

Zadik Z. , Burondukov E. , Zung A. , Reifen R. : Secular trend in Israeli population and its effect on the ICP growth model of Karlberg: Cross sectional and longitudinal data (20 year follow up), abstract . Israel Endocrine Society 1999:A27.

Hyde TM , Aaronson BA , Randolph C. , et al: Relationship of birth weight to the phenotypic expression of Gilles de la Tourette's syndrome in monozygotic twins. Neurology 1992;42(3 Pt 1):652-658.

10.

Leckman JF , Hardin MT , Riddle MA , et al: Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1991;48:324-328.

11.

Underwood LE , Van Wyk JJ : Normal and aberrant growth, in Wilson JD , Foster DW (eds): Williams Textbook of Endocrinology , 8th ed. Philadelphia, WB Saunders , 1992, 1079-1138.

12.

Muller N. , Putz A. , Klages U. , et al: Blunted growth hormone response to clonidine in Gilles de la Tourette syndrome. Psychoneuroendocrinology 1994;19:335-341.

13.

Cohen DJ , Leckman JF : Tourette syndrome: Advances in treatment and research. J Am Acad Child Psychiatry 1984;23:123-125.

14.

Erenberg G. : Treatment of Tourette syndrome with neuroleptic drugs, in Chase TN , Friehoff AJ , Cohen DJ (eds): Advances in Neurology, vol58. New York, Raven Press, 1992, 241-243.

15.

Miyake H. , Nagashima K. , Onigata K. , et al: Allelic variations of the D2 receptor gene in children with idiopathic short stature. J Hum Genet 1999 ;44:26-29.

16.

Crosley CJ : Decreased serotoninergic activity in Tourette syndrome. Ann Neurol 1979;5:596-597.

17.

Valverde I. , Penalva A. , Dieguez C. : Influence of different serotonin receptor subtypes on growth hormone secretion. Neuroendocrinology 2000;71:145-153.

18.

Thompson DL , Weltman JY , Rogol AD , et al: Cholinergic and opioid involvement in release of growth hormone during exercise and recovery . J Appl Physiol 1993;75:870-878.

19.

Sandyk R. , Bamford CR , Iacono RP , Crinnian CT : Abnormal growth hormone response to naloxone challenge in Tourette's syndrome . Int J Neurosci 1987;37:191-192.

20.

Chappell PB , Leckman JF , Scahill LD , et al: Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette's syndrome: A pilot study. Psychiatry Res 1993 ;47:267-280.

21.

Van Wattum PJ , Chappell PB , Zelterman D. , et al: Patterns of response to acute naloxone infusion in Tourette's syndrome. Mov Disord 2000;15:1252-1254.

22.

Herman BH , Hammock MK , Arthur-Smith A. , et al: Naltrexone decreases self-injurious behavior. Ann Neurol 1987;22:550-552.

23.

Barrett RP , Feinstein C. , Hole WT : Effects of naloxone and naltrexone on self-injury: A double-blind, placebo-controlled analysis. Am J Ment Retard 1989;93:644-651.

Height Distribution in Children With Tourette Syndrome

Abstract

Get full access to this article

References